MannKind Corporation (NASDAQ:MNKD) shares have been down recently owing to the FDA’s decision to extend the PDUFA date for Afrezza to July 15, 2014. MannKind Corporation (NASDAQ:MNKD) shares after opening at $6.84 moved to $6.84 on last trade day and at the end of the day closed at $ 6.41. Company price to cash ratio in past twelve months was calculated as 34.15. MannKind Corporation (NASDAQ:MNKD) showed a negative weekly performance of -6.70%.
Celldex Therapeutics (NASDAQ:CLDX) options contracts experienced a new 90-day record for call contracts where a total of 5,803 call contracts were traded in the busy trading session. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares fell -10.24% in last trading session and ended the day on $14.02. CLDX return on equity ratio is recorded as -38.40% and its return on assets is -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) yearly performance is 17.42%.
Horizon Pharma, Inc. (Nasdaq:HZNP) announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 13/713,528 entitled “Delayed-Release Tablet with Defined Core Geometry” that covers the Company’s U.S. approved product RAYOS. Horizon Pharma Inc (NASDAQ:HZNP) shares moved down -7.89 % in last trading session and was closed at $12.02 while trading in range of $11.86 – $13.18 – Horizon Pharma Inc (NASDAQ:HZNP) year to date (YTD) performance is 57.74%.
Dyax Corp. (NASDAQ:DYAX) the biopharmaceutical service provider which has finally received positive news for its plasma inhibitor called KALBITOR. Dyax Corp. (NASDAQ:DYAX) weekly performance is -17.25%. On last trading day company shares ended up $7.15. Dyax Corp. (NASDAQ:DYAX) distance from 50-day simple moving average (SMA50) is -22.28%. Analysts mean target price for the company is $13.36.